CD19, immunoglobulin level, and varied anti-cytokine autoantibodies underline dichotomous susceptibility to types of infection in patients with thymomas - Top-Institutions - MDSpire

CD19, immunoglobulin level, and varied anti-cytokine autoantibodies underline dichotomous susceptibility to types of infection in patients with thymomas

  • By

  • Zhaohong Tan

  • Areum Shin

  • Rachel Ying Min Tan

  • Dongling Wang

  • Chiung-Hui Huang

  • Sharada Ravikumar

  • Liang En Wee

  • Yvonne Fu Zi Chan

  • Ying Ying Chua

  • Sen Hee Tay

  • Anindita Santosa

  • Gladys Gek Yen Tan

  • Doo Ri Kim

  • Hyun-Il Gil

  • Jae-Hoon Ko

  • Sun Hye Shin

  • Byung Woo Jhun

  • Siew Hoon Sim

  • Yae-Jean Kim

  • Louis Yi Ann Chai

  • July 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Singapore General Hospital
    Singapore General Hospital

    Singapore, Singapore

    Key Differentiators

    • Immunology

  • #2

    Seoul National University Hospital
    Seoul National University Hospital

    Seoul, South Korea

    Key Differentiators

    • Immunology

  • #3

    Kyushu University Hospital
    Kyushu University Hospital

    Fukuoka, Japan

    Key Differentiators

    • Immunology

Original Source(s)

CD19, immunoglobulin level, and varied anti-cytokine autoantibodies underline dichotomous susceptibility to types of infection in patients with thymomas

  • by Zhaohong Tan, Areum Shin, Rachel Ying Min Tan, Dongling Wang, Chiung-Hui Huang, Sharada Ravikumar, Liang En Wee, Yvonne Fu Zi Chan, Ying Ying Chua, Sen Hee Tay, Anindita Santosa, Gladys Gek Yen Tan, Doo Ri Kim, Hyun-Il Gil, Jae-Hoon Ko, Sun Hye Shin, Byung Woo Jhun, Siew Hoon Sim, Yae-Jean Kim, Louis Yi Ann Chai

  • July 10, 2026

Related Content

Case report: Diffuse large B-cell lymphoma associated with chronic inflammation presenting as a rapidly enlarging perigraft hematoma after TEVAR

Analysis of clinicopathological features and prognosis of mesenteric versus anti-mesenteric rectal cancer: a single-center retrospective cohort study

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma